DocumentsDate added
Case Report:-
*1Ramachandran Sudarshan,2Rajeshwari G.Annigeri,3Ali IM & 4G. Sree Vijayabala
Affiliation:-
1Senior Lecturer, Department of Oral Medicine and Radiology, Best Dental Science College, Ultra Nagar, Madurai-Chennai Highway, Madurai - 625 104,India.
2Professor and Head, Department of Oral Medicine and Radiology, College of Dental Sciences & Hospital, Davangere, Karnataka, India
3Professor, College of Dental Sciences & Hospital, Davangere, Karnataka, India
4Assistant Professor in Dentistry, ESIC Medical College and PGIMSR, KK Nagar, Ashok Pillar road, Chennai, India.
Abstract:
Radiographs are the real boon not only to substantiate the diagnosis but also for the unpredicted diagnosis of lesions. One such accidentally detected lesion was odontogenic keratocyst. They are characterized by aggressive clinical behavior and high recurrence rates. We report a case of male patient who had come with chief complaint of pain in the right lower back region past 2 days. So periapical radiograph of that region was taken which showed a large radiolucent area. To confirm the extent panoramic radiograph was taken which revealed the alarming extension of approximately from the midline to the distal of third molar. Further investigations were carried out for the confirmation of diagnosis. So enucleation along with extraction of the involved teeth was done.
Key Words: Odontogenic keratocyst; Keratocystic Odontogenic Tumour; hedgehog signaling pathway.
References:
1.Madras J, Lapointe H. Keratocystic Odontogenic Tumour: Reclassification of the Odontogenic Keratocyst from Cyst to Tumour. JCDA 2008;74(2):165.
2.Barnes L, Eveson JW, Reichart P, Sidransky D, editors. Pathology and genetics of head and neck tumours. Lyon: IARC Press. WHO classification of tumours series 2005; 306.
3.Barreto DC, Bale AE, De Marco L, Gomez RS. Immunolocalization of PTCH protein in odontogenic cysts and tumors. J Dent Res 2002; 81:757-60.
4.Kumamoto H, Ohki K, Ooya K. Expression of Sonic hedgehog (SHH) signaling molecules in ameloblastomas. J Oral Pathol Med 2004; 33: 185-90.
5.Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 1971; 68: 820-3.
6.Levanat S, Gorlin RJ, Fallet S, Johnson DR, Fantasia JE, Bale AE. A two-hit model for developmental defects in Gorlin syndrome. Nat Genet 1996; 12: 85–7.
7.Kichi E, Enokiya Y, Muramatsu T, Hashimoto S, Inoue T, Abiko Y, Shimono M. Cell proliferation, apoptosis and apoptosis-related factors in odontogenic keratocysts and in dentigerous cysts. J Oral Pathol Med 2005; 34:280-6
8.de Paula AM, Carvalhais JN, Domingues MG, Barreto DC, Mesquita RA. Cell proliferation markers in the odontogenic keratocyst: effect of inflammation. J Oral Pathol Med. 2000; 29:477-82.
9.Li TJ, Browne RM, Matthews JB. Epithelial cell proliferation in odontogenic keratocysts: immunocytochemical study of Ki67 in simple, recurrent and basal cell naevus syndrome (BCNS)-associated lesions. J Oral Pathol Med 1995; 24:221-6
10.Li TJ, Browne RM, Matthews JB. Expression of epidermal growth factor receptors by odontogenic jaw cysts. Virchows Arch A Pathol Anat Histopathol 1993; 423: 137-44.
11.Kumamoto H. Molecular pathology of odontogenic tumors. J Oral Pathol Med. 2006; 35:65-74.
12.Li TJ, Browne RM, Matthews JB. Immunocytochemical expression of growth factors by odontogenic jaw cysts. Mol Pathol 1997; 50:21-7.
13.http://en.wikipedia.org/wiki/File:Sonic_hedgehog_pathway.png
14.Shear M and Speight PM (eds): Cysts of the oral and maxillofacial regions. 4th edition. Oxford, Blackwell Munksgaard 2007.
15.Reichart PA, Philipsen HP. Odontogenic tumors and allied lesions. London, UK: Quintessence Publishing 2004; 41-332.
16.Myoung H, Hong S P, Hong S-D et al. Odontogenic keratocyst : Review of 256 cases for recurrence and clinicopathologic parameters. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001; 91: 328- 33.
17.Chiang Y-C, Chao p-Z, Yang T-H, Peng B-Y, Lee F-P. Transnasal endoscopic marsupialization for a large midline maxillary odontogenic keratocyst in a 6-year-old child. Int J Pediatr Otorhinolaryngol Extra 2006; 1: 41-4.
18.Haring J I, Van Dis M L . Odontogenic keratocysts: A clinical, radiographic, and histopathologic study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1988; 66:145-53.
19.Chirapathomsakul D, Sastravaha P, Jansisyanont P. A review of odontogenic keratocysts and the behavior of recurrences. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. Jan 2006;101(1):5-9; discussion 10.
20.Philipsen HP. Keratocystic odontogenic tumor. In: Barnes L, Eveson JW, Reichart PA, Sidransky D, eds. World Health Organization Classification of Tumours: Pathology and Genetics Head and Neck Tumours. Lyon, France: IARC Press; 2005:306-7.
21.Odontogenic keratocyst. In: Sciubba JJ, Fantasia JE, Kahn LB, eds. Atlas of Tumor Pathology: Tumors and Cysts of the Jaw. 3rd ed. Washington, DC: Armed Forces Institute of Pathology; 1999:34-40.
22.Mozaffari E, Marmor DS, Alawi F. Odontogenic keratocyst with a misleading clinical and radiologic appearance. Quintessence Int. Nov-Dec 2007;38(10):837-41.
23.http://emedicine.medscape.com/article/1731868-overview#showall
24.Stolina M, Sharma S, Lin Y, et al. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol 2000;164:36.
25.Zhang L, Sun ZJ, Zhao YF, Bian Z, Fan MW, Chen Z. Inhibition of SHH signaling pathway: molecular treatment strategy of odontogenic keratocyst. Med Hypotheses 2006; 67: 1242-4.
26.Williams JA, Guicherit OM, Zaharian BI, Xu Y, Chai L, Wichterle H, Kon C, Gatchalian C, Porter JA, Rubin LL, Wang FY. Identification of a small molecule inhibitor of the hedgehog signaling pathway: effects on basal cell carcinoma-like lesions. Proc Natl Acad Sci USA 2003; 100: 4616-21.
27.Taipale J, Chen JK, Cooper MK, Wang B, Mann RK, Milenkovic L, Scott MP, Beachy PA. Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine. Nature 2000; 406:1005-9
28.Ogata S, Kubota Y, Yamashiro T, Takeuchi H, Ninomiya T, Suyama Y, Shirasuna K. Signaling pathways regulating IL-1alpha-induced COX-2 expression. J Dent Res 2007; 86: 186-91
29.http://www.chemicalforums.com/index.php?topic=51563.0.
Article citation:-
Sudarshan Ramachandran,Annigeri Rajeshwari G, IM Ali & Vijayabala Sree G. Odontogenic keratocyst - A silent tumor. Journal of pharmaceutical and biomedical sciences (J Pharm Biomed Sci.) 2013 July; 32(32): 1292-1298. Available at http://www.jpbms.info.
Copyright © 2013 Sudarshan Ramachandran. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Case report:-
Dhiraj B.Nikumbh1, Priya S.Bagle2,Chakor M.Rokade3, Sashikant Nikam4, Yogesh R.Tayade3
Affiliation:-
1* MD, Associate Professor, 2MD, Assistant Professor, 3MBBS, Assistant Lecturer, Dept Of Pathology, JMF’s ACPM medical college, Dhule, Maharashtra, India.
4 MS, Consultant Surgeon, Private Hospital. Maharashtra, India.
Author’s contribution: - All authors contributed equally to this paper.
Abstract:
Primary adenoid cystic carcinoma (ACC) of the breast is an uncommon histological form of breast cancer accounting for 0.1% of all mammary neoplasm. ACC of the breast has favorable prognosis, contrasting to the aggressive nature of the ACC at other sites like head and face especially salivary gland. It has a biological cancer of slow progression and near absence of lymph nodes metastasis. To date about 150 cases of ACC are reported in literature so far.
We are presenting a case of adenoid cystic carcinoma in a 38 year old female presented with painless mass in right breast. ACC may mimic the most common form that is intraductal carcinoma on clinical, mammography and sonography. Accurate histopathological diagnosis is always warranted, in view of its rare nature but with favorable prognosis. We report this case due to its rarity with good prognostic value if proper and early diagnosed on histopathology.
Key Words: Adenoid cystic carcinoma; breast; mammary neoplasm.
References:
1.Kontos M, Futiman IS. Adenoid cystic carcinoma of the breast. Int J Clinical Pract. 2003;57;667-72.
2.Law Ym, Quck ST, Tan PH, Wang SLJ. Adenoid cystic carcinoma of the breast. Singapore Med J. 2009;50;e8-e11.
3.Peter GN, Wolff M. Adenoid cystic Carcinoma of the breast. Report of 11 new cases: Review of the literature and discussion of biological behaviour. Cancer. 1983;52:680-6.
4.Leeming R, Jenkins M, Mendelson G. :Adenoid cystic carcinoma of the breast .Arch Surg. 1992;127:233-235.
5.Arpino G, Clark GM, Mohsim S, Bardon VJ, Elledge RM:Adenoid cystic carcinoma of the breast :Molecular marker, treatment and clinical outcome.Cancer .2002;94(8) :2119-72.
6.Musthafa S, Musthfa E, Aden H, Ertan B Nashuhi E. Adenoid cystic carcinoma of the breast .Tr. J of Medical Science .1998;28:203-205
7.Glazebrook KN, Reynolds C, Smith RL, Gimenez EI, and Boughey JC. Adenoid cystic carcinoma of the breast. American Journal of Roentgenology. 2010;194(5) :1391-6.
8.Rosen PP. Adenoid cystic carcinoma of the breast: A morphological heterogeneous neoplasm. In: Rosen PP, Fetchner RE, Norwalk CT(eds). Pathology annual 1989;Vol 24 (part 2).Norwalk, CT:Appleton and Lange;1989:P237-54.
9.Stanely MW, Tani EM, Retqwist EL, Stoog L. Adenoid cystic carcinoma of the breast. Diagnosis by fine needle aspiration .Diagnostic Cytopathology 1993;9(2): 184-7.
10.Sheen-chen SM, Eng HL, Chen WJ, Cheng YF, Ko SF. Adenoid cystic carcinoma of the breast. Truly uncommon or early over looked?. Anticancer Research. 2005;25:455-458.
11.Clement PB, Yong RH, Azzorpardi JG: Collogeneous Spherolosis of the breast. Am J Surg Path. 1987; 11:411-7.
12.Rosen PP: Adenoid cystic carcinoma of the breast: a morphologically heterogeneous neoplasm. Pathology Annual. 1989; 24:237-54.
13.Muslimani AA, Ahluwalia MS , Clark CT, Daw HA. Primary Adenoid cystic carcinoma of the breast: Case report and review of the literature. International Seminars in Surgical Oncology. 2006; 3(17):1-4.
Article citation:
Nikumbh DB et al. Primary adenoid cystic carcinoma of the breast. Journal of pharmaceutical and biomedical sciences (J Pharm Biomed Sci.) 2013 June; 31(31): 1378-1380. Available at http://www.jpbms.info.
Copyright © 2013 Nikumbh DB et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Research article:-
*1Nandedkar Prerna D.,2Sonune Sanjay.,3Chitta Shrinivas S.,4Rajurkar Sampada R
Affiliation:-
1Assistant professor, 2Professor Department of biochemistry,3Junior resident, Department of physiology,4Assistant professor, Department of PSM Government medical college, Akola (M.S), India.
Abstract:
An epidural catheter even after safe insertion & Incidence of chronic kidney disease (CKD) is increasing worldwide and show poor outcome. The correct mechanism responsible for hyperlipidemia in the patients of CKD with NS is not understood. There are very few evidences showing hyperlipidemia in patients of CKD without NS. Therefore present study is undertaken to study lipid profile pattern in CKD and compare lipid profile in CKD with NS and CKD without nephrotic syndrome.
Aims: To estimate and compare lipid profile pattern in patients of CKD with NS and CKD without NS
Settings and designs: This cross sectional study was undertaken in the Department of Biochemistry of Government Medical College Nagpur, Maharashtra.
Material and method and statistical analysis: lipid profile was analyzed and compared between 50 age & sex matched CKD withNS cases (group I) and CKD without NS cases (group II) and normal healthy subjects control of age group 20-60 years using unpaired two‐tailed Student‘t’ test.
Results: Values of total cholesterol (p<0.001), triglyceride (p<0.001), LDL-C (p<0.001) and were significantly higher in CKD with NS (group I) and CKD without NS (group II) as compare to controls but values of HDL-C (p<0.001) were significantly lower compared to controls. Also, Values of total cholesterol (p<0.001), triglyceride (p<0.001), LDL-C (p<0.001) and were significantly higher in (group I) as compared to (group II) but values of HDL-C (p>0.05) were insignificant in (group I) as compared to (group II)
Conclusion: hyperlipidemia causes high cardiovascular risk and futher renal impairement in patients of CKD with NS as compared to CKD without NS.
Key words: (CKD) Chronic kidney disease; Hyperlidemia; (NS) nephrotic syndrome.
References:
1.Culleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy D:Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 1999;56:2214-9.
2.Kasiske BL. Hyperlipidemia in patients with chronic renal disease:Am J Kidney Dis 1998;32:142-S156.
3.Weiner DE, Tighiouart H, Stark PC, Amin MG, MacLeod B, Griffith JL, et al. Kidney disease as a risk factor for recurrent cardiovascular disease and mortality. Am J Kidney Dis 2004;44:198-206.
4.Shulman NB, Ford CE, Hall WD, Blaufox MD, Simon D, Langford HG, et al; The Hypertension Detection and Follow-up Program Cooperative Group. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. Hypertension 1989;13(Suppl):I80-I93.
5.Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003;108:2154-69.
6.Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001;134:629-36.
7.Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease: J Am Soc Nephrol 1998;9(12 Suppl): S16-23.
8.IBM SPSS Statistics [computer program].Version 19.0.0. Somers (NY): IBM
9.Antonio Lacquaniti Davide Bolignano Tsimihodimos V, Dounousi E, Siamopoulos KC: Dyslipidemia in chronic kidney disease: an approach to pathogenesis and treatment. Am J Nephrol 2008; 28: 958–73.
10.Khanna UB, Nerurkar SV, Almeida AF, Taskar SP, Acharya VN:Study of hyperlipidemia in adults with nephrotic syndrome. J Postgrad Med 1985;31:140.
11.CM Chan: Hyperlipidaemia in Chronic Kidney Disease; Ann Acad Med Singapore 2005;35:31-5.
12.Prinsen BH, de Sain-van der Velden MG, de Koning EJ, Koomans HA, Berger R, Rabelink TJ: Hypertriglyceridemia in patients with chronic renal failure: possible mechanisms. Kidney Int Suppl 2003; 84:121–4.
Article citation:-
Nandedkar Prerna D.,Sonune Sanjay., Chitta Shrinivas S., Rajurkar Sampada R. Comparative study of hyperlipidemia in patients of CKD with nephrotic syndrome and CKD without nephrotic syndrome. Journal of pharmaceutical and biomedical sciences (J Pharm Biomed Sci.) 2013 July; 32(32): 1396-1399.Available at http://www.jpbms.info.
Copyright © 2013 Nandedkar Prerna D.,Sonune Sanjay.,Chitta Shrinivas S.,Rajurkar Sampada R.. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Clinical study
*1Gulri A, 1Sood R, 2Dodwad V & 3Nagpal S
Affiliation:-
1Post graduate 2nd year, 2HOD & Professor, 3Post graduate 3rd year, Department of periodontics,I.T.S-CDSR ,Murad Nagar ,Ghaziabad,U.P, India.
Abstract:
Alendronate (ALN), an aminobisphosphonate,is known to inhibit osteoclastic bone resorption andwas proposed to have osteostimulative properties in vivo and in vitro as shown by an increase in matrix formation. The present study aims to explore the efficacy of a 1% ALNgel compared to a placebo gel as a local drug delivery system in adjunct to scaling and root planing (SRP) for the treatment of patients with chronic periodontitis.
A total of 20 sites with pocket depth of 4-6 mm were treated witha 1%ALN or placebo gel in adjunct to scaling and root planing. The ALN gel was prepared by adding ALN to a polyacrylic acid–distilled water mixture. Clinical parameters (gingival index, plaque index, probing depth [PD], and relative attachment level [RAL]) were recorded at baseline and 15 and 30 days.It was concluded that GI, PI , PPD , RAL is reduced in the test site where 1% ALN was placed in adjunct to scaling and root planning.
Key Words: Alendronate; Scaling and root planing (SRP); Gingival crevicular fluid.
References:
1.Chapple IL, Matthews JB. The role of reactive oxygenand antioxidant species in periodontal tissue destruction.Periodontol 2000 2007;43:160-232.
2.SlotsJ.Subgingivalmicroflora and periodontal disease.JClinPeriodontol 1979;6:351-82
3. Baylink DJ, Finkelman RD, Mohan S. Growth factors to stimulate bone formation. J Bone Miner Res 1993;8(Suppl. 2):S565-S72.
4.Goziotis A, Sukhu B, Torontali M, DowhaniukM,Tenenbaum HC. Effects of bisphosphonates APD andHEBP on bone metabolism in vitro. Bone 1995;
16(Suppl. 4):317S-27S.
5.Tenenbaum HC, Torontali M, Sukhu B. Effects of bisphosphonates and inorganic pyrophosphate on osteogenesis in vitro. Bone 1992;13:249-55.
6.Giuliani N, Pedrazzoni M, Negri G, Passeri G, ImpicciatoreM, Girasole G. Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promoteearly osteoblastogenesis in young and aged mice in vivo.Bone1998;22:455-61.
7.Vitte´C, Fleisch H, Guenther HL. Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast- mediated resorption. Endocrinology 1996;137:2324-33.
8. Yaffe A, Fine N, Alt I, Binderman I. Effect of bisphosphonate on alveolar bone resorption following mucoperiosteal flap surgery in the mandible of rats. JPeriodontol 1995;66:999-1003.
9. Yaffe A, Fine N, Binderman I. Regional accelerated phenomenon in the mandible following mucoperiosteal flap surgery. J Periodontol 1994;65:79-83.
10. Yaffe A, Iztkovich M, Earon Y, Alt I, Lilov R, BindermanI. Local delivery of an amino bisphosphonate prevents the resorptive phase of alveolar bone following mucoperiosteal
flap surgery in rats. J Periodontol 1997;68:884-9.
11. Wang HL, Weber D, McCauley LK. Effect of long-term oral bisphosphonates on implant wound healing:Literature review and a case report. J Periodontol2007;78:584-94.
12. Silness J, Lo¨e H. Periodontal disease in pregnancy. II.Correlation between oral hygiene and periodontal condition.ActaOdontolScand1964;22:121-35.
13. Lo¨eH ,Silness J. Periodontal disease in pregnancy. I. Prevalence and severity. ActaOdontolScand 1963;21:533-51.
14.Reddy GT, Kumar TM, Veena KM. Formulation and evaluation of alendronate sodium gel for the treatment of bone resorptive lesions in periodontitis. Drug Deliv 2005;12:217-22.
15. Lin JH, Chen IW, deLuna FA.On the absorption of alendronate in rats.JPharmSci1994;83:1741-46.
16. Fleisch H. Bisphosphonates: Mechanisms of action.Endocr Rev 1998; 19:80-100.
17. Srisubut S, Teerakapong A, Vattraphodes T, TaweechaisupapongS. Effect of local delivery of alendronate on bone formation in bioactive glass grafting in rats.OralSurg Oral Med Oral Pathol Oral Radiol Endod2007;104:e11-e16.
18.Luckman SP, Coxon FP, Ebetino FH, Russell RGG,Rogers MJ. Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: Evidence from structureactivity relationships inmacrophages. J Bone Miner Res 1998;13:1668-78.
19.Rocha M, Nava LE, Va´zquez de la Torre C, Sa´nchez-Ma´ rin F, Garay-Sevilla ME, Malacara JM. Clinical and radiological improvement of periodontal disease in patients with type 2 diabetes mellitus treated with alendronate: A randomized, placebo-controlled trial. JPeriodontol2001;72:204-09.
20.Brunsvold MA, Chaves ES, Kornman KS, Aufdemort TB, Wood R. Effects of a bisphosphonate on experimental periodontitis in monkeys. J Periodontol 1992;63:825-30.
21.Needleman IG, Pandya NV, Smith SR, Foyle DM. The role of antibiotics in the treatment of periodontitis J Periodontol • January 2012 Sharma, Pradeep17(part 2 – controlled drug delivery). Eur J ProsthodontRestor Dent 1995;3:111-17.
Article citation:-
Gulri A, Sood R ,Dodwad V & Nagpal S. Clinical efficacy of 1% alendronate gel as a local drug delievery system in the treatment of chronic periodontitis. Journal of pharmaceutical and biomedical sciences (J Pharm Biomed Sci.) 2013 July; 32(32): 1343-1347. Available at http://www.jpbms.info.
Copyright © 2013 Gulri A, Sood R, Dodwad V & Nagpal S. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Research article:-
*1G.Bhawani,2Ashutosh Kumar,3KSN Murthy & 4Neera Kumari
Affiliation:-
1Associate professor, Department of pharmacology, GSL Medical College & hospital, Rajahmundry, India
2Chief Interventional Cardiologist, GSL medical College & hospital, Rajahmundry, India.
3Head of the department, Department of pharmacology, GSL Medical College & hospital, Rajahmundry, India.
4Assistant professor, Department of Physiology,SRI Krishna medical college, Muzzafarpur, India.
Author’s contributions-All authors contributed equally to this paper.
Abstract:
Aim of study: The present study was designed with the aim of elucidating whether there exists any association between significant QTcd ( QT interval dispersion) and occurrence of complications in patients of acute myocardial infarction(AMI).
Methods & results: 60 patients with AMI admitted in intensive cardiac care unit during the period march 2012 to October 2012 were enrolled following inclusion/exclusion criteria’s. Variations in the QTcd were calculated for the patients from the time of admission till the day of discharge at a fixed time per day. Association between QTcd in (msec) and the eight complications taken as end point for the study was established. The mean time and age of the study population was 8±3.19 hours, 59 years respectively. A total of 48 patients developed complications. QTcd was significantly higher with complications of ventricular tachyarrythmias (7/60,83.6±24.6, CI 95%), left ventricular failure ( 7/60,76.5±14.1, CI 95%) . QTcd was very high in patients with pos tinfarct angina (3/60,108±36.030) and cardiogenic shock (6/60, 96±26.01). The most common complication observed was A-V block with significant QTCd in (15/60 , 63.16±32.2) Sudden death within 48 hours of thrombolysis having very high QTcd even at the time of Admission was observed in (5/60, 99.5 ± 13.79 to 110.62 ± 19.34 ).
Conclusion: QTcd was significantly higher in patients who developed complications except those with pericardial effusion and thromboembolism. There was no significant co-relation between the location of MI, QTc dispersion and development of complications. QTc dispersion was significantly very high in those patients with sudden death even at the time of admission.
Finally QT and QTc dispersion at admission and during stay in hospital may be used as an important non-invasive marker for prediction of various complications of AMI.
Key words: Acute myocardial infarction; QT interval; QTc dispersion; myocardial infarction complications.
References:
1.Bulatao RA , Stephens PW. Global estimates and projections of mortality by cause:Population,Health and nutrition Department; World Bank, 1007;1992.
2.Gaziano JM, Ridker PM, Libby P. Primary and secondary prevention of coronary heart disease. In: Bonow RO, Mann DL, Zipes DP, Libby P,eds. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 9th ed. Philadelphia, Pa: Saunders Elsevier;2011:chapter 49.
3.Anderson ME, Al-Khatib SM, Roden DM, Califf RM. Cardiac repolarization: current knowledge,critical gaps and new approaches to drug development and patient management.Am Heart J.2002;144:769-81. Pubmed
4.Kautzner J, Malik M; QT dispersion and its clinical utility, PACE 20 1997 2625-40.
5.Statters D.J, Malik M, Ward D.E, Camm A.J; QT dispersion. problems of methodology and clinical significance, J Cardiovasc Electrophysiol 1994;5:672-685.Pubmed
6.Higham PD et al QT dispersion does reflect regional variation in ventricular recovery circulation 1992;86(suppl 1):392.
7.Hohnloser SH et al QT dispersion in the surface ECG as a parameter of increased electrical vulnerability in acute myocardial ischaemia Z kardiol 1993;82:678-82.Pubmed
8.Levine SJ, Shah M: Increased QT dispersion associated with ventricular tachyarrhythmias in first 48 hours of myocardial infarction. Journal of Noninvasive Cardiology 1997; 1:8–21.
9.Shah C.P, Thakur R.K, Reisdorff E.J, Lane E, Aufderheide T.P, Hayes O.W; QT dispersion may be a useful adjunct for detection of myocardial infarction in the chest pain center, Am Heart J 136 1998 496-8.Pubmed
10.Schwartz PJ, Wolf S: QT-interval prolongation as predictor of sudden death in patients with myocardial infarction. Circulation 1978;57:1074-7. Pubmed
11.Glancy JM, Garrat CJ, de Bono DP dynamics of QT dispersion during myocardial infarction and ischaemic. Int .J .cardiology 1996 ; 57:55-60.Pubmed
12.Aitchison JD et al. time dependent variability of QT dispersion after acute myocardial infarction and its relation to ventricular fibrillation. A prospective study Heart (British cardiac society) 2000;84:504-8.Pubmed
13.Bodi V et al QT dispersion within the 1st 6months after an acute myocardial infarction: relationship with systolic function, left ventricular volume, infarct related artery status and clinical out come international journal of cardiology 2001;80(1):37-45.Pubmed
16.Kabakci G et al what is the optimal evaluation time of QT dispersion after acute myocardial infarction for the risk stratification. Angiology 2001;52(7)463-820.Pubmed
17.Perkiomaki JS, Koistinen MJ, YliMayry, Herikuri HV. Dispersion of QT interval in patients with and without susceptibility to ventricular tachyarrythmias after previous myocardial infarction.Amercardiol 1995;28:174-9.Pubmed
18.Bjorn W , Dale J effect of very early intravenous streptokinase infusion in patients with evolving myocardial infarction, Actor Med Scand 1998;223:15-8.Pubmed
Article citation:-
Bhawani G.,Kumar Ashutosh ,Murthy KSN, Kumari Neera. Study of QT interval dispersion in acute myocardial infarction and its relationship with complications. Journal of pharmaceutical and biomedical sciences (J Pharm Biomed Sci.) 2013 July; 32(32): 1425-1431.Available at http://www.jpbms.info
Copyright © 2013 Bhawani G., Kumar Ashutosh, Murthy KSN, Kumari Neera K. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.